iBio (IBIO) Stock: Buy, Sell, or Hold?
IBIO - iBio, Inc. Common Stock
$0.72
-0.07 (-8.44%)
▼
5d:
-6.33%
30d:
-40.18%
90d:
-50.5%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When IBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IBIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IBIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IBIO is currently trading at $0.72, which is considered oversold relative to its 30-day fair value range of $0.88 to $1.25.
Technical Outlook: Technically, IBIO is in a strong downtrend. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: IBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.69 (+692.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IBIO is in a strong downtrend. The price is currently testing key support at $0.71. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: IBIO scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.69 (+692.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.88 -
$1.25
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 692.5% below Wall St target ($5.69)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.88 -
$1.25
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.71
Resistance Level
$0.95
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.32
Wall Street Target
$5.69
(+692.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 23, 2026 10:54 PM ET
Data refreshes hourly during market hours. Next update: 11:54 PM
Data refreshes hourly during market hours. Next update: 11:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$63 | 54 HOLD |
